Eric Nuttall: Oil/Gas in 2026 — Where I’m Investing, Plus Prices, Supply, Demand
Eric Nuttall, partner and senior portfolio manager at Ninepoint Partners, shares his outlook for oil and natural gas in 2026, emphasizing that
Eric Nuttall, partner and senior portfolio manager at Ninepoint Partners, shares his outlook for oil and natural gas in 2026, emphasizing that
Bayan Mining and Minerals Ltd (ASX: BMM; ‘BMM’ or ‘the Company’) is pleased to report significant high-grade rare earth element (REE) results
European Lithium Ltd (ASX: EUR, FRA: PF8, OTC: EULIF) (“European Lithium” or the “Company”) advises that it has completed a sale of
Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top
Canadian oil and gas stocks have faced a rollercoaster ride over the past few years. However, analysts remain optimistic about the global oil
American Lithium Minerals (OTCID:AMLM) announced it has taken a 19 percent stake in privately held Cunningham Mining, giving it exposure to precious
Astral Resources NL (ASX: AAR) (Astral or the Company) is pleased to report assay results received from a 17-hole reverse circulation (RC)
Jindalee Lithium Limited (Jindalee, or the Company; ASX: JLL, OTCQX: JNDAF) is pleased to report assay results from the drilling program at
Trading in the securities of Cyprium Metals Limited (‘CYM’) will be halted at the request of CYM, pending the release of an
TSX-V: WLRFrankfurt: 6YL Standards of Disclosure for Mineral Projects and its Companion Policy 43-101CP with an effective date of January 6, 2026.
Global markets may look serene, but beneath the surface, political risk is surging.Bank of England Governor Andrew Bailey is warning that geopolitical
Markets are repricing power, not growth.Netflix just went all-cash on Warner Bros. Discovery at $27.75 a share, removing stock-risk and forcing Paramount
Corvus Pharmaceuticals (NASDAQ: CRVS) shares more than doubled on Jan. 20 after announcing positive Phase 1 trial data for “soquelitinib” – its
Apple stock (NASDAQ: AAPL) slid nearly 3% on Tuesday, even as Evercore and Citi issued constructive notes ahead of the company’s earnings